Then, the Western blotting analysis highlighted an increase in N-cadherin and Vimentin, and a decrease in epithelial marker E-cadherin, under the IL-1β treatment (p < 0.0005), while the treatment with BC at both concentrations blocked the EMT process in IL-1β/BC co-treatments (see Figure 4B). The gene discussed is CDH2; the disease is breast cancer.